NEW YORK, NY / ACCESSWIRE / January 8, 2018 / U.S. markets continued their impressive run on Friday to close the week with impressive gains. Both the Dow and the Nasdaq have posted its largest four-day gain to start a year since 2006. The Dow Jones Industrial Average spiked 0.88 percent to close at 25,295.87, up 2.3 percent for the week, while the Nasdaq Composite Index jumped 0.83 percent to close at 7,136.56, up 3.4 percent for the week.
"Valuations long term are stretched but people are looking past that because of the tax cuts," said John Serrapere, director of research at Arrow Funds, according to CNBC.
RDI Initiates Coverage on:
Amicus Therapeutics, Inc.
Synergy Pharmaceuticals, Inc.
Amicus Therapeutics stock moved 3.43% lower Friday, to close the day at $14.91. The stock recorded a trading volume of 2,365,090 shares, which was above its three months average volume of 2,231,614 shares. In the last year, Amicus Therapeutics shares have traded in a range of 5.07 - 16.60. The share price has gained 194.08% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $13.62 is greater than its 200-day moving average of $13.33. Shares of Amicus Therapeutics have gained roughly 15.63 percent in the past month and are up 3.61 percent year-to-date.
Access RDI's Amicus Therapeutics, Inc. Research Report at:
On Friday, shares of Synergy Pharmaceuticals, Inc. recorded a trading volume of 14,851,181 shares, which was above the three months average volume of 7,183,206 shares. The stock ended the day 10.66% lower at 2.18. The share price has gained 29.76% from its 52 week low with a 52 week trading range of 1.68 - 7.15. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.07 is below its 200-day moving average of $3.02. Shares of Synergy Pharmaceuticals, Inc. have gained roughly 18.48 percent in the past month and are down 2.24 percent year-to-date.
Access RDI's Synergy Pharmaceuticals, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.